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Abstract
Background: Serum miRNAs profiles between papillary thyroid carcinoma (PTC) patients with non-131I and 131I-avid
lung metastases are differentially expressed. These miRNAs have to be further validated and the role of these miRNAs
in the molecular function level of thyroid cancer cell lines has not been investigated.
Methods: Expression levels of six identified miRNAs were assessed via quantitative real-time PCR (qRT-PCR) in the
serum of eligible patients. Dual-luciferase reporter assay was used to determine the potential target of miR-106a.
Cell viability and apoptosis were evaluated by MTT assay and flow cytometry analysis, respectively. The change of
gene expression was detected by qRT-PCR and western blotting analysis. In vitro iodine uptake assay was
conducted by a γ-counter.
Results: Compared to PTC patients with 131I-avid lung metastases, miR-106a was up-regulated in the serum of patients
with non-131I-avid lung metastases. The results of dual-luciferase reporter assay demonstrated that miR-106a directly
targeted retinoic acid receptor beta (RARB) 3′-UTR. miR-106a-RARB promoted viability of thyroid cancer cells by
regulating MEKK2-ERK1/2 and MEKK2-ERK5 pathway. miR-106a-RARB inhibited apoptosis of thyroid cancer cells by
regulating ASK1-p38 pathway. Moreover, miR-106a-RARB could regulate the expression of sodium iodide symporter,
TSH receptor and alter the iodine uptake function of thyroid cancer cells.
Conclusions: miRNA-106a, directly targeting RARB, associates with the viability, apoptosis, differentiation and the
iodine uptake function of thyroid cancer cell lines by regulating MAPK signaling pathway in vitro. These findings
in the present study may provide new strategies for the diagnosis and treatment in radioiodine-refractory
differentiated thyroid carcinoma.
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Background
Differentiated thyroid cancer (DTC) is increasing all over
the world [1], as an indolent tumor, DTC patients have
excellent prognosis following conventional treatments
based on adequate surgical management, radioactive
iodine (RAI) ablation and thyroid-stimulating hormone
(TSH) suppression [2, 3]. Radioiodine is considered to
be the initial systemic and efficient treatment for
metastatic DTC patients. Unfortunately, approxi-
mately 30 % of patients with advanced, metastatic
DTC have radioiodine-refractory disease [4]. Losing
the ability to concentrate radioiodine in metastatic
sites from DTC most likely owns to less differenti-
ated types transformation (dedifferentiation) [5]. This
problem creates a major obstacle in radioiodine
treatment for those patients while the mechanisms
underlying the dedifferentiation transformation of
DTC are still not well understood.
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It is well accepted that constitutive activation of mitogen-
activated protein kinase (MAPK) signaling pathway plays
a significant role in the tumorigenesis of thyroid carcin-
oma and it also could promote the dedifferentiation of
thyroid-cancer cells. Regarding to this fact, disease-
specific molecular targets of therapy is studied much
popularly [6]. MAP3K2 (MEKK2) is a serine/threonine
kinase that belongs to the MEKK/STE11 family of
MAP kinase kinase kinases, which can activate JNK1/2
[7], p38 [8], ERK5 [9] and ERK1/2 [10] pathways. How-
ever, its role in thyroid cancer has not been clearly
studied by now.
Recently, the involvement of miRNAs in proliferation,
differentiation and apoptosis has been defined and sev-
eral reports have displayed the changes in miRNA pro-
files in differentiated thyroid cancers as compared to
normal thyroid tissues [11–15]. But the role of miRNAs
in the differentiation/dedifferentiation of DTC, especially
in the expression of sodium iodide symporter (NIS) and
NIS-mediated iodine uptake, is not clearly understood.
Lakshmanan et al. found that miR-339-5p directly bound
to hNIS-3′UTR and miR-339-5p overexpression de-
creased NIS-mediated radioiodine uptake in HEK293
cells expressing exogenous hNIS [16].
One of our previous studies analyzed the differentially
expressed serum miRNAs profiles between papillary thy-
roid carcinoma (PTC) patients with non-131I and 131I-
avid lung metastases [17]. But the function of these miR-
NAs in thyroid cancer has not been reported. In the
current study, the role of miRNA-106a in the viability,
apoptosis, migration, invasion and differentiation (fo-
cused on the expression of NIS and TSH receptor and
the ability of iodine uptake) of thyroid cancer cell lines
was investigated.
Methods
Serum samples and cell culture
The serum samples of PTC patients with 131I-avid and
non-131I-avid lung metastases were collected from
September 2010 to July 2014 at our department. The in-
clusion/exclusion criteria and the method to process the
samples have been described before [17]. Total RNA
from serum sample was extracted and purified using the
miRNeasy Mini Kit (Qiagen, Valencia, CA) according to
the manufacturer’s instructions. The study was approved
by the Institutional Ethics Review Board of our hospital
and informed consent was obtained from each patient.
Human PTC cell line CGTH-W3 (Institute of Bio-
chemistry and Cell Biology, SIBS, CAS, Shanghai, China)
and anaplastic thyroid carcinoma (ATC) cell line 8505C
(Institute of Biochemistry and Cell Biology, SIBS, CAS,
Shanghai, China) were cultured in RPMI-1640 (Gibco,
Cat. # 11875–093) supplemented with 10 % fetal bovine
serum (Gibco, Cat. # 16000–044). HEK 293 T (Institute
of Biochemistry and Cell Biology, SIBS, CAS, Shanghai,
China) was maintained in Deulbecco’s Modified Eagle
medium (Gibco, Cat. # 10565–018) supplemented with
10 % fetal bovine serum (Gibco, Cat. # 16000–044). All
the cells were incubated at 37 °C in a humidified cham-
ber supplemented with 5 % CO2. U0126 and SB203580
were obtained from Selleck Chemicals (Houston, TX,
Cat. # S1102 and S1076). All-trans retinoic acid (RA)
was obtained from Sigma-Aldrich (Cat. # R2625).
Different managements of cells
8505C-miR106a(−) and 8505C-scrambled control
miArrest™ miRNA inhibitor (GeneCopoeia, Cat. # HmiR-
AN0026-AM03), scrambled control (GeneCopoeia, Cat. #
CmiR-AN0001-AM03) and Lenti-Pac™ HIV Expression
Packaging Kit (GeneCopoeia, Cat. # HPK-LvTR-20) were
used to construct Lenti-Pac-miRNA-106a inhibitor and
Lenti-Pac- scrambled control. After transfected to pack-
aging cells (HEK 293T), the medium was collected and
centrifuged at 4,000 × g for 10 min at room temperature
to pellet cell debris, and then filtered through a 0.45 μm
filter. Target cells (8505C) were transfected with Lenti-
Pac-miRNA-106a inhibitor [8505C-miR106a(−)] or Lenti-
Pac-scrambled control (8505C-scrambled control).
8505C-miR106a(−) + RARB(−)
8505C-miR106a(−) cells were transfected with Human
retinoic acid receptor beta (RARB) Silencer® Select
siRNA (Ambion, target sequence: TCAGACGGCCT-
TACCCTAAAT, Cat. # 4392420) using Lipofectamine
2000 (Invitrogen, USA, Cat. # 11668019) following the
manufacturer’s instructions.
8505C-miR106a(−) + ASK1(−)
Selective inhibitor of ASK1, (2,7-dihydro-2,7-dioxo-3H-
naphtho [1,2,3-de] quinoline-1-carboxylic acid ethyl ester;
NQDI-1) (Sigma, Cat. # SML0185), was used to inhibit
ASK1 by pretreating the 8505C-miR106a (−) cells.
8505C-miR106a(−) + MAP3K2(+)
8505C-miR106a(−) cells were transiently transfected
with MAP3K2 (NM_006609) Human cDNA ORF Clone
(OriGene, Cat. # RC223988) using 100 μl Opti-MEM I
(Gibco, Cat. # 51985091) and 3 μL Turbofectin 8.0 (Ori-
Gene, Cat. # TF81001).
CGTH-W3-miR106a(+) and CGTH-W3-control vector
The amplified human miR-106a gene was digested with
BamHI and EcoRI restriction enzymes and was cloned
into the lentiviral vector pCDH-CMV-MCS-EF1-copGFP
(System Biosciences, Cat. # CD511B-1). The pCDH-miR
106a lentiviral vector was transformed into E. coli DH5α,
then pCDH-miR106a was purified using a plasmid kit
(Qiagen, Cat. # 12143) according to the manufacturer’s
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instructions. Then pCDH-miR106a was packaged into
HEK 293 T cells with the pPACK packaging mix using a
lentivector expression system (System Biosciences) accord-
ing to the manufacturer’s instructions. After transfection to
packaging cells for 48 h, the medium was collected and
centrifuged at 4,000 × g for 10 min at room temperature to
pellet cell debris, and then filtered through a 0.45 μm filter.
Target cells (CGTH-W3) were transfected with Lenti-
pCDH-miR106a [CGTH-W3-miR106a(+)] or Lenti-pCDH
(CGTH-W3-control vector).
CGTH-W3-RARB(−)
CGTH-W3 cells were transfected with Human RARB Si-
lencer® Select siRNA (Ambion, target sequence: TCA-
GACGGCCTTACCCTAAAT) using Lipofectamine 2000
(Invitrogen, Cat. # 11668019) following the manufac-
turer’s instructions.
Dual-luciferase reporter assay
A fragment of 3′UTR of RARB (NM_000965) containing
the putative miR-106a binding sites was amplified by
PCR using the following primers:
wt- RARB (forward): 5′- GGGTACCCCTACTTCAA
ACATTCCCCAG-3′;
wt- RARB (reverse): 5′-CCCTCGAGGGTGAGAAC
TAAGAAACTGACA-3′;
3′UTR of RARB with a mutant seed sequence of





Then pGL3-RARB 3′UTR–wt, pGL3-RARB 3′UTR-
mut vectors were constructed. For the reporter assay,
HEK 293T cells were plated into 24-well plates and co-
transfected with the above constructs and miR-106a
mimics/miR-negative controls using the Lipofectamine
2000 reagent (Invitrogen, Cat. # 11668019). After 48 h,
the cells were harvested and assayed using the dual-
Luciferase Reporter Assay system (Promega, Cat. #
E1910) according to the manufacturer’s instructions.
MTT: cell viability assays
The cell viability were evaluated using 3-(4, 5-
dimethylthiazol-2-yl) 22, 5-diphenyltetrazolium brom-
ide (MTT) assay. Cells were seeded in sextuplicate in
96-well microtiter plates at a density of 1 × 104 cells/
well in 100 μL medium. The plates were incubated in a
37 °C humidified incubator for adherence overnight.
Then after 0, 24, 48, 72 and 96 h culture, 20 μL of 5 g/
L MTT (Amresco, Cat. # 0793-500MG) was added, re-
spectively. The medium was removed after 4 h, and the
reaction was then stopped by the addition of DMSO
and measured at A570 in a Microplate spectrophotom-
eter (Spectra Max Plus, Molecular Devices, Sunnyvale,
CA). The results were expressed as percentage, based
on the ratio of the absorbance between the treated cells
and the controls (100 %). Experiments were repeated
three times.
Apoptosis flow cytometry analysis
ApoAlert Annexin V-FITC kit (Clontech, Cat. # 630109)
was used to assess the cell apoptosis. Parental CGTH-
W3 and 8505C cells and transfected sublines were
seeded in 6-well plates at 1 × 105 per well. Cells were
harvested 72 h later and stained with Annexin V-FITC
and propidium iodide according to the manufacturer’s
protocol. Cell samples were analyzed on a FACScan
Analyzer and apoptotic fractions were determined. Ex-
periments were repeated three times.
Measurement of caspase-3 activity
The caspase-3 activity in parental CGTH-W3 and 8505C
cells and transfected sublines were measured by using
Caspase-3 Activity Assay Kit (Beyotime Biotech, Cat. #
C1116) according to the manufacturer’s instructions. The
assay is based on the hydrolysis of the peptide substrate
acetyl-Asp-Glu-Val-Asp p-nitroanilide (Ac-DEVD-pNA)
by caspase-3, resulting in the release of a pNA moiety. Ab-
sorbance values were measured at 405 nm. Results were
adjusted to the total protein content, and activity was
expressed as μmol pNA/h/mg of total protein.
Scratch-wound migration and transwell invasion assays
Wound healing assays were used to determine cell mi-
gration. Briefly, cells grown in 6-well plates as confluent
monolayers were mechanically scratched by using a
200 μL pipette tip and then washed with PBS to remove
the debris. Cells were cultured for 24 h to allow wound
healing. Each scratch-wound area was calculated using
the ImageProPlus 6.0 program (Media Cybernetics Inc.,
Bethesda, MD). Transwell invasion assays were per-
formed with Matrigel (BD Biosciences) coated on the
upper surface of the transwell chamber (Corning).
Twenty four hours later, cells invaded through the
Matrigel membrane were fixed with 4 % paraformalde-
hyde and stained with crystal violet. The number of in-
vaded cells was counted for analysis.
RNA extraction and quantitative real-time polymerase
chain reaction (qRT-PCR) analysis
Total RNA in cultured cells was isolated using Trizol re-
agent (Invitrogen, Cat. # 15596–026) following the manu-
facturer’s instructions, and stored at −80 °C. RevertAidTM
First Strand cDNA Synthesis Kit (Fermentas, Cat. #
K1622) was used for reverse transcription. qRT-PCR was
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performed in the ABI PRISM 7500 Sequence Detection
System (Applied Biosystems, Foster City, CA) using the
SYBR Green RT-PCR kit (Qiagen, Cat. # 204147). All
values were normalized using an internal reference (U6,
for miRNAs; and GAPDH, for mRNAs). Relative expres-
sion was estimated by the comparative Ct method (2-ΔΔCt)
[18]. A 2-ΔΔCt >3 or < 0.3 was deemed to indicate statis-
tical significance.
Western blot analysis
Equal amounts of cell lysates were separated by 12 % SDS-
PAGE, and electrophoretically transferred to PVDF mem-
brane. The membrane was blocked and probed with pri-
mary antibody (anti-ASK1, anti-phospho-ASK1, anti-p38,
anti-phospho-p38, anti-ERK1/2, anti-phospho-ERK1/2,
anti-ERK5, anti-phospho- ERK5, anti-JNK, anti-phospho-
JNK from Cell Signaling Technology; anti-MEKK2, anti-
NIS, anti-TSHR from Santa Cruz; anti-β-actin from Sigma)
followed by HRP (horseradish peroxidase)-labeled goat
anti-mouse IgG (Abcam) or HRP-labeled goat anti-rabbit
IgG (Abcam). Chemiluminescence was used to analyze pro-
tein levels and β-actin was used as a protein loading con-
trol. Semi-quantitative analysis was conducted by using
ImageJ 1.49v (National Institutes of Health, USA).
In vitro iodine uptake assay
Parental CGTH-W3 and 8505C cells and transfected sub-
lines were seeded in 24-well plates at 5 × 104 per well over
night. After washed with 1 mL HBSS twice, 1 mL HBSS
containing 0.1 μCi Na125I and 1 μmol/L NaI was added.
After 30 min at 37 °C in a humid atmosphere, cells were
collected and washed with ice-cold HBSS. Radioactivity
was counted in a γ-counter.
Statistics analysis
Comparisons of continuous variables between two groups
were performed using the Student’s t test while categorical
variables were performed using the Chi-square test. (a P <
0.05 was considered a statistically significant difference).
Analyses were performed using the Statistical Package for
the Social Sciences, version 20.0 (SPSS, Chicago, IL, USA)
and Graph Pad prism Version 5.0 (GraphPad Software,
Inc, USA).
Results
miR-106a is up-regulated in the serum of patients with
non-131I-avid lung metastases
Forty seven PTC patients with non-131I-avid lung metas-
tases (A) and 72 with 131I-avid lung metastases (B) were
identified in our institution. Demographic and clinical
features of these patients are summarized in Table 1. Six
candidate miRNAs (miR-106a, miR-34c-5p, miR-1281,
miR-1915, miR-2861, miR-3196) which were most chan-
ged between the serum of patients with non-131I-avid
lung metastases or 131I-avid lung metastases [12] were
validated in the current study. The results of qRT-PCR
confirmed the up-regulation of miRNA-106a (P < 0.01).
However, the expressions of the other five miRNAs had
no significant differences between the two categories of
patents (Fig. 1).
miR-106a is differently expressed in different thyroid
cancer cell lines and altered after transfection
Expression levels of miR-106a were detected in CGTH-
W3 and 8505C cells by qRT-PCR. The result showed
that the level of miR-106a in 8505C was up-regulated
when compared to CGTH-W3 (Fig. 2a). miR-106a over-
expression models in CGTH-W3 cells [CGTH-W3- miR
106a(+)] and miR-106a knockdown models in 8505C
cells [8505C-miR106a(−)] were established by infected
with lentiviral vectors carrying the miR-106a gene and
miR-106a inhibitor gene, respectively (Fig. 2b-c). The data
of qRT-PCR indicated that levels of miR-106a in CGTH-
W3- miR106a(+) cells was significantly up-regulated while
the level of miR-106a in 8505C-miR106a(−) cells was sig-
nificantly down-regulated.
miR-106a directly targets RARB 3′-UTR (miR-106a-RARB)
The 3′-UTR of RARB mRNA contains a complementary
site for the seed region of miR-106a (Fig. 2d). To deter-
mine whether RARB is a direct target of miR-106a, the
RARB 3′-UTR and the mutant containing the miR-106a
binding sites were subcloned into a reporter vector
downstream of the luciferase gene. Dual-luciferase re-
porter assays showed that the relative luciferase activity
of the reporter that contained wild-type 3′-UTR of
RARB mRNA was significantly decreased in miR-106a-
overexpressing cells compared with control cells. How-
ever, mutation of the predicted binding site of miR-106a
on the RARB 3′-UTR rescued the luciferase activity
(Fig. 2e). Furthermore, the results of qRT-PCR and west-
ern blotting showed that overexpression of miR-106a
significantly decreased the expression level of RARB,
whereas inhibition of miR-106a induced reduction of
RARB mRNA and protein (Fig. 2f, g).
miR-106a-RARB promote the viability of thyroid cancer
in vitro
The results of MTT assays demonstrated that overex-
pression of miR-106a or inhibition of RARB could pro-
mote cell viability in CGTH-W3 cells while inhibition of
miR-106a could suppress cell viability in 8505C cells
(Fig. 3a, b) and the reduced proliferation effect could re-
sult from cell cycle arrest (Fig. 3c).
In order to investigate the potential mechanism of miR-
106a-RARB regulating the viability of thyroid cancer cells,
8505C-miR106a(−) cells with overexpression of MAP3K2
(MEKK2) were used. And U0126 (10 μM), an inhibitor of
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ERK1/2 and ERK5 (Fig. 4e), was used to determine the
significance of signaling pathway (as an effect of losing
function of ERK1/2 and ERK5). The results of MTTassays
showed that 8505C-miR106a(−) cells with overexpression
of MAP3K2 promoted cell viability while 8505C and
CGTH-W3-miR106a(+) cells treated with U0126 inhibit
cell viability (Fig. 3a, b). Western blotting showed that
MAP3K2 and its downstream gene ERK1/2/5 were down-
regulated in 8505C-miR106a(−) cells when compared to
that in 8505C control cells. However, similar to that in
8505C-miR106a(−) +MAP3K2(+) cells, MAP3K2 and its
downstream gene ERK1/2/5 were up-regulated in 8505C-
miR106a(−) + RARB(−) cells (Fig. 4a, b). In CGTH-W3
cells, MAP3K2 and its downstream gene ERK1/2/5 were
up-regulated by overexpression of miRNA-106a or down-
regulation of RARB (Fig. 4a, b). Together with the results
of cell viability assays and western blotting, these data
demonstrated that miR-106a-RARB could increase the
viability of thyroid cancer cells by activating MEKK2-
ERK1/2 and MEKK2-ERK5 pathway.
miR-106a-RARB inhibit apoptosis of thyroid cancer cells
CGTH-W3- miR106a(+) and 8505C-miR106a(−) cells
were used to determine their apoptosis level by flow cy-
tometry analysis. The results of flow cytometry analysis
demonstrated that overexpression of miR-106a or inhib-
ition of RARB could reduce apoptosis in CGTH-W3
cells while inhibition of miR-106a could promote apop-
tosis in 8505C cells (Fig. 4c). And caspase-3 activity of
these cells paralleled with the cellular apoptotic vulner-
ability (Fig. 4d).
Further, in order to investigate the potential mechan-
ism of miR-106a-RARB regulating the apoptosis level of
thyroid cancer cells, 8505C-miR106a(−) cells with inhib-
ition of ASK1 by NQDI-1 were used. And SB203580
(20 μM), an inhibitor of p38 (Fig. 4e), was used to deter-
mine the significance of signaling pathway (as an effect of
losing function of p38). Western blotting showed that p-
ASK1 and its downstream gene p-p38 were up-regulated
in 8505C-miR106a(−) cells when compared to that in
8505C control cells. However, similar to that in 8505C-
Table 1 Clinical and demographic features of patients with non-131I-avid and 131I-avid lungs metastases
Clinical Characteristics Groups P value
non-131I-avid (N = 47) 131I-avid (N = 72)
Age/years 0.55
Median (range) 43 (28–60) 42 (27–55)
Gender 0.90
Male (%) 21 (44.7) 33 (45.8)
Female (%) 26 (55.3) 39 (54.2)
Tg level (ng/ml) 0.77
Median (range) 1213.5 (304.7–3121.9) 1324.3 (324.9–3249.5)
TgAb level (IU/ml) 0.72
Median (range) 45.6 (10–125.6) 43.8 (10–150.3)
Histological diagnosis PTC PTC –
Primary tumor –
T stage –
T1 17 27 –
T2 19 30 –
T3 9 12 –
T4 2 3 –
N stage –
N0 0 0 –
N1 46 70 –
Nx 1 2 –
Chest CT scan Diffuse small nodules Diffuse small nodules –
131I up take in lungs Close to upper limbs Diffuse lung uptake –
Extent of disease No other metastasis No other metastasis –
Other cancer history No No –
Other treatment No No –
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miR106a(−) + ASK1(−) cells, p-ASK1 and its downstream
gene p-p38 were down-regulated in 8505C-miR106a(−) +
RARB(−) cells. In CGTH-W3 cells, p-ASK1 and its down-
stream gene p-p38 were down-regulated by overexpres-
sion of miRNA-106a or down-regulation of RARB
(Fig. 4a, b). Together with the results of apoptosis flow
cytometry analysis and western blotting, these data
demonstrated that miR-106a-RARB could decrease
apoptosis of thyroid cancer cells by inhibiting ASK1-
p38 pathway.
miRNA-106a could increase the abilities of invasion and
migration in thyroid cancer cells
8505C-miR106a(−) and CGTH-W3-miR106a(+) cells
were used to determine the effect of miRNA-106a on
the the abilities of migration and invasion in thyroid
cancer cells. The results of scratch-wound migration and
transwell invasion assays demonstrated that down-
regulation of miRNA-106a in 8505C cells could decrease
the abilities of invasion (Fig. 5a) and migration (Fig. 5b)
while overexpression of miRNA-106a in CGTH-W3 cells
could promote the abilities of invasion (Fig. 6c) and mi-
gration (Fig. 6d).
miR-106a-RARB could regulate the expression of NIS, TSHR
and alter the iodine uptake function of thyroid cancer
in vitro
As showed in the results of western blotting, overexpres-
sion of miR-106a or inhibition of RARB could reduce
the expression of NIS and TSHR in CGTH-W3 cells,
inhibition of miR-106a could increase the expression of
NIS and TSHR in 8505C cells and inhibition of RARB
or overexpression of MAP3K2 in 8505C-miR106a(−)
cells could counteract the effect. However, inhibition of
ASK1 in 8505C-miR106a(−) cells did not show the same
results [NIS and TSHR expression did not change in
8505C-miR106a(−) and 8505C-miR106a(−) + ASK(−)]
(Fig. 6a). Further, the iodine uptake abilities of these cells
were studied and the results showed that overexpression
of miR-106a or inhibition of RARB could reduce the
iodine uptake ability in CGTH-W3 cells. While inhib-
ition of miR-106a could regain the iodine uptake ability
in 8505C cells and inhibition of RARB or overexpression
of MAP3K2 could counteract the effect (Fig. 6b). In
addition, the influence of RA, the ligand of RARB, on
125I uptake in these models was also studied and the re-
sults demonstrated that RA could increase the ability of
iodine uptake in thyroid cancer cells under the existence
Fig. 1 The results of qRT-PCR (ΔCt value) of the six candidate miRNAs (miR-106a, miR-34c-5p, miR-1281, miR-1915, miR-2861, miR-3196). Smaller ΔCt value
indicates higher expression. (*, p< 0.01)
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of RARB (Fig. 6b). Presence or absence of its ligand RA,
the expression level of RARB in the cells was not signifi-
cantly changed (Fig. 6c).
Discussion
Circulating miRNAs, known as stable cell-free miRNAs
in serum or plasma, are passively and selectively released
to blood by various cells, and may act as transmitter or
messenger in cell communication. During disease, aber-
rantly expressed miRNAs in the diseased cells are re-
leased into the circulation, and the circulating miRNA
profile is endued with the disease properties [19]. In the
current study, miR-106a detected in patients’ serum
could be produced from primary tumors, or metastatic
PTC tumor, or even related with tumor micro environ-
ment. miR-106a, acting as an Onco-miR, has been found
to be associated with carcinogenesis in many carcinomas
[20–23] however its role in thyroid cancer has not been
reported. miR-106 family members, as the key players in
stem cell self-renewal, are highly induced during the early
stages of cell reprogramming [24]. miR-106a is known to
function in tumor-initiating cells and regulate tumor
differentiation through the retinoblastoma (Rb) pathway
[22]. Liu et al. reported that miR-106a could specifically
repress expression of the retinoblastoma family member
RBL2 and miR-106a overexpression resulted in rapid
tumor growth and poor differentiation [23]. In the current
study, miR-106a, directly targeting RARB, might promote
viability of thyroid cancer cells by activating MEKK2-
ERK1/2 and MEKK2-ERK5 pathway and increase the
apoptosis of thyroid cancer cells by inhibiting ASK1-p38
pathway. Moreover, we also found that miRNA-106a-
RARB could regulate the expression of NIS, TSHR and
alter the iodine uptake function of thyroid cancer cells
through MAPK signaling pathway.
Many signaling pathways have been reported associ-
ated with the NIS gene expression and radioiodine up-
take in thyroid cancer. Accumulating evidence suggests
Fig. 2 a, relative expression of miR-106a in CGTH-W3 and 8505C; b, miR-106a overexpression models [CGTH-W3- miR106a(+)]: CGTH-W3 cells transfected
with lentiviral vectors carrying the miR-106a gene; c, miR-106a knockdown models [8505C-miR106a(−)]: 8505C cells transfected with miR-106a inhibitor
gene; d, the seed structure of the 3′ UTR of RARB and the miR-106a binding site; e, results of dual-luciferase reporter assays; f, RARB mRNA expression in
different management of cells detected by qRT-PCR; g, RARB protein expression in different management of cells by western blotting. (*, p< 0.01)
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Fig. 3 a, MTT Cell viability assays: relative cell viability in parental 8505C and transfected sublines [*, P< 0.01, miR106a(−) and U0126 vs. control; #, P< 0.01,
miR106a(−) + RARB(−) and miR106a(−) +MAP3K2 vs. miR106a(−)]; b, MTT Cell viability assays: relative cell viability in parental CGTH-W3 and transfected
sublines [*, P< 0.01, miR106a(+) and RARB(−) vs. control; #, P< 0.01, miR106a(+) + U0126 vs. miR106a(+)]; c and d, flow cytometry analysis of cell cycle in
8505C and 8505C-miR106a(−)
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that aberrant activation of the MAPK pathway plays a
central role in the destruction of NIS-mediated iodide ac-
cumulation in patients with DTC [25]. The BRAFV600E
mutation, one of the key activators of the MAPK pathway,
is highly prevalent in recurrent radioiodine-refractory
papillary thyroid cancer and is associated with loss of NIS-
mediated 131I uptake [26–29]. PBF(pituitary tumour-
transforming gene [PTTG]-binding factor) is a proto-
oncogene that seems to play a crucial part in diminished
membrane targeting of NIS [30, 31]. PI3K-AKT-mTOR
and NOTCH signaling pathway also have been found to be
linked to the regulation of thyroid-specific gene expression.
Activation of the PI3K-AKT pathway plays a fundamental
role in thyroid tumorigenesis and is involved in downregu-
lation of genes controlling iodide metabolism in patients
with DTC [32, 33]. However, overexpression of NOTCH1
in thyroid cancer cells can induce differentiation and stimu-
late NIS expression [34]. Epigenetic alterations, including
DNA hypermethylation and histone deacetylation, also play
an important part in silencing thyroid-specific genes, espe-
cially NIS [35, 36].
RARB, a member of the thyroid-steroid hormone
receptor superfamily of nuclear transcriptional regula-
tors, binds retinoic acid, the biologically active form
Fig. 4 a,b,e western blotting analysis of parental CGTH-W3 and 8505C cells and transfected sublines for proteins in MAPK signaling pathway
(SB, SB203580. *, p < 0.01); c, flow cytometry analysis:apoptosis in parental CGTH-W3 and 8505C cells and transfected sublines (*, p< 0.01); d, caspase-3
activity in parental CGTH-W3 and 8505C cells and transfected sublines (*, p< 0.01)
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of vitamin A which mediates cellular signaling in em-
bryonic morphogenesis, cell growth and differenti-
ation. In thyroid cancers, RA induces redifferentiation
of cancer cells and expression of the NIS gene. As a re-
sult, radioiodine uptake of tumors and serum Tg level
are expected to increase with RA treatment [37, 38].
And the loss of retinoid receptors might occur during
the loss of differentiation and tumor progression of
PTC [39]. Kogai et al. reported that RA stimulation of
the NIS in MCF-7 breast cancer cells was meditated by
the insulin growth factor-I/phosphatidylinositol 3-
kinase and p38 MAPK signaling pathways and an in-
hibitor of p38 MAPK could significantly reduce iodide
uptake in both all-trans retinoic acid-stimulated MCF-7
cells and TSH-stimulated FRTL-5 cells [33].
Some limitations have to be mentioned in the current
study. Firstly, the relative expression of miR-106a was
statistically different in the serum of PTC patients with
iodine avid and non-avid lung metastases, but the differ-
ence in the mean levels was modest and there was a
large amount of overlap between the groups. In addition,
all remaining experiments are in cell models with very
large differences in miR-106a expression, not at all mod-
eling the difference found in humans. Secondly, lacking
of primary and metastasized tumor tissues (fresh or
formalin-fixed and paraffin-embedded sample) made it
unable to detect any histotype difference between pri-
mary and metastasized tumors and measure miR-106a
and RARB in tumor tissues level besides in serum level
which could further strength the significance of the find-
ings in the current study.
Conclusions
In summary, the role of miRNA-106a in the viability,
apoptosis, migration, invasion, differentiation and iodine
uptake function of thyroid cancer cell lines were investi-
gated in the current research and the results indicated
Fig. 6 a, western blotting analysis of parental CGTH-W3 and 8505C cells
and transfected sublines for NIS and TSHR; b, iodine uptake ability in
parental CGTH-W3 and 8505C cells and transfected sublines (*, p< 0.01).
c, western blotting analysis (together with semi-quantitative analysis of
blots) of RARB with and without RA
Fig. 5 a, transwell invasion assay in 8505C-miR106a(−) and control cells
(*, P< 0.05); b, scratch-wound migration assay in 8505C-miR106a(−)
and control cells (*, P< 0.05); c, transwell invasion assay in CGTH-W3-
miR106a(+) and control cells (*, P< 0.05); d, scratch-wound migration
assay in CGTH-W3-miR106a(+) and control cells (*, P< 0.05)
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that miRNA-106a directly targeting RARB associated
with the viability, apoptosis, differentiation and the iod-
ine uptake function of thyroid cancer cell lines by regu-
lating MAPK signaling pathway in vitro. These findings
may provide new strategies for the diagnosis and treat-
ment in radioiodine-refractory DTC.
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